NASDAQ:CRTX Cortexyme (CRTX) Stock Price, News & Analysis $1.52 -0.13 (-7.88%) As of 07/1/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsTrendsBuy This Stock About Cortexyme Stock (NASDAQ:CRTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cortexyme alerts:Sign Up Key Stats Today's Range$1.51▼$1.6750-Day Range$0.84▼$1.6552-Week Range$1.78▼$40.66Volume267,948 shsAverage Volume620,672 shsMarket Capitalization$45.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Read More Receive CRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter. Email Address CRTX Stock News HeadlinesCrism Thera Regulatory NewsAugust 4, 2024 | lse.co.ukCortexyme : Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name - Form 8-K - Marketscreener.comAugust 1, 2022 | marketscreener.comMTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. July 2 at 2:00 AM | Paradigm Press (Ad)Cortexyme Completes Phase 1 Single, Multiple Ascending Dose Trial of Potential Alzheimer's Disease Treatment - Marketscreener.comJuly 27, 2022 | marketscreener.comMCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Business WireJuly 27, 2022 | businesswire.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Business WireJuly 27, 2022 | businesswire.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Marketscreener.comJuly 27, 2022 | marketscreener.comMCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Yahoo FinanceJuly 27, 2022 | finance.yahoo.comSee More Headlines CRTX Stock Analysis - Frequently Asked Questions How have CRTX shares performed this year? Cortexyme's stock was trading at $1.85 on January 1st, 2025. Since then, CRTX shares have decreased by 17.8% and is now trading at $1.52. View the best growth stocks for 2025 here. How were Cortexyme's earnings last quarter? Cortexyme, Inc. (NASDAQ:CRTX) released its quarterly earnings results on Monday, August, 9th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.05. When did Cortexyme IPO? Cortexyme (CRTX) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers. How do I buy shares of Cortexyme? Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cortexyme own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cortexyme investors own include Alibaba Group (BABA), Enterprise Products Partners (EPD), NVIDIA (NVDA), Tesla (TSLA), Pfizer (PFE), Meta Platforms (META) and AT&T (T). Company Calendar Last Earnings8/09/2021Today7/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryHealth Care Technology Current SymbolNASDAQ:CRTX CIK1145404 Webwww.cortexyme.com Phone(650) 910-5717FaxN/AEmployees55Year Founded2012Profitability EPS (Trailing Twelve Months)($2.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$89.94 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.96% Return on Assets-63.53% Debt Debt-to-Equity RatioN/A Current Ratio9.92 Quick Ratio9.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.97 per share Price / Book0.42Miscellaneous Outstanding Shares30,151,000Free Float21,739,000Market Cap$49.75 million OptionableNot Optionable Beta1.40 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CRTX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.